Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Update

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 25,945 shares, a decrease of 33.7% from the December 15th total of 39,109 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average daily trading volume, of 34,460 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily trading volume, of 34,460 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.7% of the shares of the company are short sold.

Sensei Biotherapeutics Trading Down 10.1%

Shares of Sensei Biotherapeutics stock traded down $1.17 during mid-day trading on Friday, hitting $10.44. 74,872 shares of the stock were exchanged, compared to its average volume of 75,564. The stock has a market capitalization of $13.15 million, a price-to-earnings ratio of -0.55 and a beta of 0.28. Sensei Biotherapeutics has a twelve month low of $5.00 and a twelve month high of $18.35. The company has a 50-day simple moving average of $9.41 and a 200 day simple moving average of $9.14.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, November 14th. The company reported ($3.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.11) by $0.49. Equities research analysts forecast that Sensei Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

SNSE has been the topic of several research reports. HC Wainwright lowered Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research report on Saturday, December 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $55.00.

Insider Activity at Sensei Biotherapeutics

In other news, major shareholder James Peyer sold 3,507 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $7.96, for a total transaction of $27,915.72. Following the transaction, the insider directly owned 155,142 shares in the company, valued at $1,234,930.32. The trade was a 2.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 27,907 shares of company stock valued at $287,280. 23.20% of the stock is currently owned by company insiders.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.